If you feel ill with fever, flu-like symptoms or respiratory illness, please call us to reschedule your appointment. Please Do Not Bring Children Under age 16 to Appointments.

The Future of IBD Treatment

Over a million Americans suffer from Inflammatory Bowel Disease every day. Now, a new drug may be available soon to change the entire face of the disease for those who suffer.

Second Genome, Inc. is a leader in the development of medicines using the bacteria that already exists in the human body. Each human body has a microbiome, comprised of an estimated 100 trillion bacteria. Second Genome is using innovative scientific methods to use these bacteria for IBD treatment and other diseases that are currently under treated in the medical field.

The two most common forms of IBD are Crohn’s disease and ulcerative colitis, both cause the GI tract to swell, making it difficult to digest food, absorb nutrition, and eliminate waste. The new drug, called SGM-1019, was announced in January 2015 as a molecule inhibitor, meaning it identifies and prevents the original driver of IBD through the body’s own microbiome system. If effective, it may have the ability to completely treat IBD safely and effectively with little or no side effects. The drug is delivered orally, and contains a small molecule that may be able to prevent IBD symptoms completely.

“Our scientists have identified a novel and important relationship between microbiome modulation of the target of SGM-1019 and inflammatory bowel disease. SGM-1019 has the potential to address a critical unmet need in inflammatory bowel disease treatment as a safe and well-tolerated oral therapy with an important disease modifying effect,” says Peter DiLaura, President, and CEO of Second Genome.

As of now, the drug is called SGM-1019 and is entering Phase I of a clinical trial. It has already completed a double blind, placebo controlled test, which went well and was successful with no significant adverse events. The next step in the Phase I trial is to explore multiple ascending doses to identify an optimal dose for future studies. Ideally, the Phase I trial should be completed later this year, although it may take much longer for the drug to make it to pharmacy shelves.

The goal of IBD treatment is to improve the quality of life for millions of Americans. Currently, there is no single ideal therapy for the treatment of the disease. However, there are several treatment options, including prescription antibiotics, corticosteroids, Aminosalicylates, and immunomodulators. Still, not every medication works for every patient, and there is no absolute cure. Second Genome’s platform is based in microbiome science, aiming to transform lives with medicines developed through this innovative science to treat multiple diseases where needs are currently not being met.

The genius of Second Genome’s proprietary Microbiome Discovery Platform is the ability to explain the complex relationship between the microbiome and the human body. Once this relationship is explored, Second Genome can isolate and identify more microbiome modulated drug targets. Second Genome obtained exclusive rights to SGM-1019 from an undisclosed biopharmaceutical partner.

At Granite Peaks we can treat your IBD conditions.